A Study to Evaluate Safety, Tolerability, PK and PD of HLX01 in Patients With CD20-positive B-cell Lymphomas

B-cell Lymphomas Clinical Trial

Official title:
A Phase Ia, Multi-centers, Open-label, Dose-escalation Clinical Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HLX01 (a Potential Rituximab Biosimilar) in Patients With CD20-positive B-cell Lymphomas

Status Completed

Clinical Trial Summary

To evaluate safety, tolerability, pharmacokinetics and pharmacodynamics of HLX01 (a potential rituximab biosimilar) in patients with CD20-positive B-cell lymphomas.

Clinical Trial Description

This was a phase Ia, multicenter, open-label, dose-escalation clinical study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics characteristics of HLX01 injection in patients with CD20-positive B-cell lymphomas. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03218072
Study type	Interventional
Source	Shanghai Henlius Biotech
Contact
Status	Completed
Phase	Phase 1
Start date	May 4, 2014
Completion date	January 31, 2015

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02891590` - Safety, Tolerability and PK of BTK Inhibitor DTRMWXHS-12 in Patients With B-Cell Lymphomas	Phase 1
Completed	`NCT01068392` - Oxaliplatin and Prednisolone (Ox-P) for Patients With Relapsed or Refractory Marginal Zone B-cell Lymphoma(MZL)	Phase 2
Terminated	`NCT01744912` - Ublituximab in Combination With Lenalidomide in Patients With B-Cell Lymphoid Malignancies	Phase 1
Completed	`NCT01478269` - Prognosis Of Patients With Aggressive B-Cell Lymphoma, Treated With Rituximab+Anthracycline Regimen	N/A
Withdrawn	`NCT05160064` - Long-term Registry of Patients Treated With Loncastuximab Tesirine
Recruiting	`NCT02247609` - Evaluation of 4th Generation Safety-designed CAR T Cells Targeting High-risk and Refractory B Cell Lymphomas	Phase 1/Phase 2
Recruiting	`NCT00801216` - High-Dose Sequential Chemoimmunotherapy for B-Cell Lymphomas With Central Nervous System Involvement	Phase 2
Completed	`NCT01613300` - Study of OFATUMUMAB as Part of the Scheme of Reduced Intensity Conditioning in High Risk Non-Hodgkin Lymphoma B Patients	Phase 2
Active, not recruiting	`NCT05773040` - A Phase 1 Study of JV-213 Autologous CD79b-targeting Chimeric Antigen Receptor T-cell Therapy in Adults With Relapsed or Refractory B-cell Lymphomas	Phase 1